Who Really Protects Patients in Clinical Trials? With Dr. Lara Shirikjian
In this episode of Power to the Patients, Brandon Li speaks with Dr. Lara Shirikjian, board-certified psychiatrist and Medical Director at CenExel, about what it truly takes to build effective, ethical, and scalable psychiatric research programs.
Drawing on over 20 years of clinical and research ex…
Why Serotonin Isn’t Outdated, Our Thinking Is
Psychiatric drug development may be overcomplicating progress while overlooking effective treatments. Brandon Li speaks with Dr. Jacob Jacobsen, neuroscientist and CEO of Evecxia Therapeutics, about why clinical outcomes should matter more than novel mechanisms.
Jacobsen argues that the field’s fix…
Why Dr. Ken Sharlin Believes Most Neurological Diseases Are Reversible
In this episode of Power to the Patients, Brandon Li speaks with Dr. Ken Sharlin, a neurologist and principal investigator with decades of experience across clinical practice, functional medicine, and clinical research. Dr. Sharlin shares his journey from traditional academic neurology to a systems…
Precision Medicine Got Kidney Disease Wrong—Until Now
Kidney disease affects 37 million people and is now the ninth leading cause of death globally. Yet despite its scale and severity, it has largely been absent from the precision medicine revolution that reshaped oncology.
In this episode of Power to the Patients, Jason Coloma, CEO of Maze Therapeuti…
Why Psychiatry Is Finally Breaking Free From Dopamine
Psychiatry has long been considered one of the most complex and least understood areas of medicine. While other therapeutic fields have advanced rapidly with clear biomarkers and objective endpoints, mental health has remained rooted in subjective assessments and decades-old treatment approaches.
I…
70% Remission for Postpartum Depression? The Psychedelic Breakthrough
Psychedelic therapy for postpartum depression shows breakthrough results. Reunion Neuroscience CEO Greg Mayes details luvesilocin clinical trials. While many developers focus on treatment-resistant depression, Reunion is carving a path through postpartum depression and adjustment disorder. Greg sha…
How Neuroplasticity Is Shaping the Next Generation of Psychiatric Medicines
In this episode of Power to the Patients, host Brandon Li speaks with Dr. Aaron Koenig, Chief Medical Officer at Delix Therapeutics, about the emerging field of neuroplasticogens and the effort to develop medicines that promote neuroplasticity without the hallucinogenic effects associated with psyc…
The Gout Narrative Keeping Patients Sick and What Crystalys Therapeutics Is Doing Differently
Gout is often treated solely as a lifestyle problem. James Mackay calls that a myth.
In this episode of Power to the Patients, host Brandon Li sits down with James, CEO and co-founder of Crystalys Therapeutics, to unpack why gout has been misunderstood, under-prioritized, and under-innovated for d…
Reversing Chemo failure in ovarian cancer with Thomas Zindrick
For many ovarian cancer patients, platinum-based chemotherapy works well at first. Then resistance begins: the tumor adapts, treatment loses effect, and clinical options narrow.
That is the clinical problem Thomas Zindrick and his team at Genelux Corporation are trying to address with their lead ca…
Why Enveda Teaches AI to Read Nature's Chemistry
Drug discovery from nature is not a new idea. It is one of pharma’s oldest ideas.
Aspirin, metformin, and many other small molecule drugs trace their origins back to natural sources. Historically, the bottleneck was complexity. Finding a single active molecule inside a plant with 10,000 unique comp…
موتور جستجوی پادکست
می توانید از وب سایت ما برای جستجوی پادکست های3,824,896و قسمت های195,788,159بر اساس افراد، مکان ها یا موضوعات استفاده کنید.
سرمایه‌گذاری روی دانش بیشترین بازده را دارد؛ پس پادکست گوش می‌دهم.
‐ Benjamin "Llamacorn" Franklin
ویرایش
از کمک شما برای بروز نگهداشتن پایگاهدادههای پادکست سپاسگزاریم
